Objective: The purpose of this pilot trial was to determine whether rates of contact dermatitis following cutaneous antisepsis for central catheter placement were similar among neonates treated with chlorhexidine gluconate and povidone-iodine. Chlorhexidine gluconate absorption was also evaluated.
Introduction
Percutaneously inserted central catheters (PICCs) can cause significant neonatal morbidity. [1] [2] [3] [4] Catheter-related bloodstream infection (CRBSI), one of the most common complications of central venous catheterization in neonates, increases length of hospital stay, hospital costs, potential for antibiotic toxicity 2 and neurologic morbidity. 5 Ten percent povidone-iodine (PI) has been widely used for antisepsis before PICC placement in neonates. However, laboratory findings consistent with transient hypothyroidism from systemic absorption of iodine after iodophor scrubs have been reported by several authors. 6, 7 Transient hypothyroidism has not been widely reported in North America. 8, 9 Recent trials in adults and neonates suggest that a cutaneous chlorhexidine gluconate (CHG) scrub before central venous catheter (CVC) or peripheral catheter insertion may be more effective than PI for prevention of CRBSI in adults and catheter colonization in neonates. [10] [11] [12] [13] No current CHG-based antiseptic has been approved by the Federal Drug Administration (FDA) for use in neonates for intravenous catheter placement.
In this pilot randomized trial of critically ill neonates <2 months of age who required a PICC, we set out to determine if cutaneous antisepsis before PICC insertion with 2% CHG in an alcohol-based solution was as well-tolerated as 10% PI.
Methods

Subjects
This pilot trial was carried out at five Level III neonatal intensive care units; two community hospitals (Wheaton Franciscan Healthcare, St Joseph and Aurora Sinai Medical Center) and three university teaching hospitals (Children's Hospital of Wisconsin, Children's Hospital of Philadelphia and Boston Children's Hospital). Study units ranged from 24 beds to 50 beds. Institutional review boards at each center approved the protocol and informed consent was obtained from the parents of participating neonates.
The FDA limited study enrollment to neonates who were at least 7 days old and weighed more than 1500 g because of concerns for the development of contact dermatitis in low-birth-weight neonates exposed to topical CHG. Exclusion criteria included X60 days of age at enrollment, catheterization p48 h, prior discharge home and conditions of altered skin integrity.
Treatment arms
Neonates were block randomized to one of two treatment groups: 10% PI or 2% CHG. After randomization insertion sites were cleansed with appropriate antiseptic before catheter placement. In the CHG group, ampoules containing 3 ml of 2% CHG (Enturia Inc., Leawood, KS, USA) were used to cleanse PICC sites. The site was dressed with a polyurethane dressing that was changed weekly while the catheter remained in situ. The same antiseptic was used to re-cleanse the site with each dressing change. All peripheral intravenous catheter sites were also cleansed with the same antiseptic used for PICC insertion. CHG ampoules containing 0.67 ml of 2% CHG were used to cleanse peripheral intravenous sites in CHG-treated neonates.
All catheters were placed using standard sterile techniques with wide barriers. Decisions to remove catheters were made independently by the primary care team. Peripheral blood cultures were performed at the discretion of the primary care team in neonates with signs of sepsis.
Culture techniques
Catheters were aseptically removed and the last 5 cm of the tip was cultured using the semiquantitative method of Maki et al.
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Standard laboratory methods were used to identify organisms colonizing the catheter tip. 15 
Dermatitis assessment
Catheter sites (PICC and peripheral) were inspected daily for the presence and severity of contact dermatitis by a study nurse using a dermatitis severity scale (Table 1) .
Serum chlorhexidine gluconate concentrations
Blood CHG concentrations were determined at single center using liquid chromatography with tandem mass spectrometry (National Medical Service, Willow Grove, PA, USA) following catheter placement, just before the first dressing change and immediately after the first dressing change. The lower limit for quantitation of CHG was 10 to 20 ng ml À1 using a 0.5 ml sample of whole blood.
Primary outcome
Catheter tip colonization was defined by a semiquantitative catheter colony count of X15 colony-forming units. 14 Colonization was selected as a primary outcome because of its association with CRBSI and bloodstream infection (BSI) without a source. 14, 16, 17 BSI without a source was defined by all of the following: a positive peripheral blood culture during the time of catheterization or within 24 h of catheter removal, clinical signs and symptoms of a BSI, antibiotic therapy for X7 days and no other documented primary site of infection. 18 The catheter tip was not colonized or was colonized with organisms other than that grown from the blood. A CRBSI was defined as a BSI in which there was concordance between organisms grown from the blood and catheter tip.
Severe contact dermatitis was defined by a dermatitis score of X2 (Table 1) .
Data collection and analysis
Data obtained on each patient included demographic information, 24 h Score for Neonatal Acute Physiology (SNAP) score, 19 catheter type, medications, catheter location, attempts to place catheter, number of CHG ampoules used for PICC and peripheral intravenous catheter placement, sites of infection during catheterization, days of catheterization, reason for catheter removal, invasive treatments, and laboratory and clinical findings to assess infection. After data collection, sheets were checked for errors and missing data, the data were double entered into a data set for analysis using Statistical Analysis System 9.0 for the PC (SAS Institute, Cary, NC, USA).
All results were based on intention to treat. Baseline differences between treatment groups were compared using Student's t-test or Wilcoxon rank-sum analysis for continuous variables and w 2 -analysis for categorical variables. Differences in primary outcome (catheter colonization, BSI without a source and CRBSI) rates (per 100 catheters) and incidence (per 1000 catheter days) were compared. Relative risk ratios and 95% confidence intervals were determined using the PI treatment group as the reference group. The rate of severe contact dermatitis (dermatitis score X2) and distribution of contact dermatitis scores were compared using w 2 -analysis. Median differences in contact dermatitis scores were compared using Wilcoxon rank-sum analysis.
As a pilot trial with a goal of enrolling 150 neonates, the study was not powered to evaluate differences in CRBSI, BSI or catheter tip colonization. The trial was designed primarily to evaluate the tolerance and absorption of 2% CHG in an alcohol base and provide preliminary data to support a larger trial including smaller (<1500 g), younger (<7 days of age) neonates. The trial would have 80% power at an a error of 0.05 to show a 0.5 point difference in mean contact dermatitis score among treatment groups assuming 400 catheter sites (150 PICC and 250 peripheral intravenous catheter sites) were included in the trial.
Results
Because of the entry criteria stipulated by the FDA, one center, which enrolled a single neonate, withdrew from the trial after the first year. Just 47 neonates were enrolled at other centers during the first 2 years (2005 to 2007) of study enrollment. After 2 years of slow enrollment the sponsor chose to terminate the study. A total of 65 eligible infants were not enrolled in the trial because of parental refusal or lack of availability of a study member for enrollment. The groups were similar for baseline demographic characteristics, severity of illness measures, patient characteristics at time of catheter placement and treatments during catheterization ( Table 2) .
Outcomes
Catheter tip colonization occurred in 3 of 24 (13%) of CHG-treated neonates and 1 of 24 (4%) PI-treated neonates (P ¼ 0.61). Similarly, there was no detectable difference between BSI rates among treatment groups (Table 3 , P ¼ 0.99). The incidence of BSI was similar among treatment groups (2.8 vs 3.0 per 1000 catheter days among CHG-vs PI-treated neonates, P ¼ 0.96). CRBSIs did not occur in either treatment group. Four neonates in each treatment group were treated for at least 7 days of antibiotics for a presumed BSI (that is, signs and symptoms of sepsis with a negative blood culture). Septicemia evaluations were similar among treatment groups (7 of 24 CHG vs 9 of 24 PI, P ¼ 0.54).
Rates of other infections such as pneumonia (8 vs 4%), cellulitis (0 vs 4%) and urinary tract infections (8 vs 0%) were similar between CHG-and PI-treated neonates (Pp0.49). Severe contact dermatitis (dermatitis scoreX2) did not occur (upper 95% confidence limit (95% UCL) 5.7%) in CHG-(PICC, n ¼ 24; PIV, n ¼ 29) or PI (95% UCL 6.4%) -treated catheter sites (PICC, n ¼ 24; PIV, n ¼ 23). Only one PI catheter site had any signs of dermatitis (dermatitis score ¼ 1), which resolved without treatment.
Serum chlorhexidine gluconate concentration
Measurements of serum chlorhexidine concentration determinations were planned for the first 20 neonates enrolled at the primary center (Wheaton Franciscan Healthcare, St Joseph Hospital). Because the study was terminated early only 10 neonates had concentrations measured (Table 4 ). Five of ten had measurable serum concentrations (>10 ng ml À1 ) after the first cutaneous application of antisepsis; seven of ten had measurable serum concentrations (range 13 to 100 ng ml À1 ) sometime during catheterization. The maximum serum concentration (100 ng ml À1 , Table 4 ) occurred after the third dressing change in a 27-day-old neonate who was born at 28 weeks' gestation.
Serum concentrations increased following the first or second dressing change in six of seven neonates with measurable concentrations on at least two separate occasions. experienced a serious episode of contact dermatitis at the site of a novel CHG-impregnated dressing. Strict entry criteria limited subject accrual and the trial was discontinued before enrolling sufficient neonates to adequately power the trial to evaluate differences in dermatitis rates. Chlorhexidine was detectable in the blood of over two-thirds of neonates who had concentrations measured. Chlorhexidine gluconate, a cationic biguanide, rapidly and effectively kills most skin pathogens. 20, 21 It has residual effects on the skin to provide antisepsis for up to 24 h. CHG antisepsis is well tolerated in pediatric and adult patients with few toxic side effects. We previously reported severe contact dermatitis with the use of a novel CHG-impregnated dressing that was placed over catheter sites after insertion. 18 Most episodes occurred in neonates who were less than a week old and p28 weeks' gestation at birth. Occlusiveness, pressure created by the dressing, CHG or a combination of all three factors may have been responsible for episodes of severe contact dermatitis at the dressing sites. In a time sequence trial to evaluate a multifactorial approach to reduce CRBSI, Andersen et al. 22 noted that 4 of 36 (11%) neonates <1000 g developed contact dermatitis after a 2% aqueous chlorhexidine scrub. There were no episodes of contact dermatitis in 49 study neonates who were X1000 g. In our trial there were no episodes of dermatitis at the 53 catheter sites of relatively mature (32.41±2.9 weeks), heavy (2085±846 g) neonates. In a cohort of neonates whose mean gestational age and birth weight were 35 ± 5.1 weeks and 2.45 ± 1.07 kg, respectively, cutaneous antisepsis with a 0.5% CHG solution in an alcohol base for peripheral catheter insertions did not cause dermatitis at insertion sites that necessitated catheter removal or local treatment. Abbreviations: CHG, chlorhexidine gluconate; ND, none detected. Blood chlorhexidine gluconate concentrations were measured after the catheter placement, just before the first dressing change and after the first dressing change. Cumulative exposures were based on the volume contained in an ampoule of 2% chlorhexidine gluconate. Ampoules used to place CVCs contain 3 ml; ampoules used for peripheral intravenous insertion contain 0.67 ml. The lower level of detection of chlorhexidine gluconate was 10-20 ng ml À1 using a 0.5 ml sample of whole blood.
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These results suggest that CHG-induced contact dermatitis is uncommon in heavier, mature neonates. Anaphylactic reactions have occurred in adults following application of CHG to mucosal membranes or with the use of CHGimpregnated catheters. 23, 24 Impregnated catheters are not approved for use in neonates and there have not been reports of neonatal anaphylactic reactions to CHG. During this study no anaphylactic reactions occurred.
Cutaneous antisepsis with CHG before CVC insertion effectively reduces risk for CRBSI infections in adults who require CVCs. 11 To date there have been no randomized trials showing CHG to be more efficacious than PI in preventing CRBSI in neonates. Because most adult CVC are in place less than 7 days, adequate cutaneous antisepsis before catheter placement will effectively prevent most CRBSI. Neonatal PICCs are often in situ greater than 10 days when hub contamination becomes a more likely source for CRBSI. 25 In a cohort trial 25 nested in a randomized trial 18 to assess the efficacy of an antibiotic lock solution in neonates, Garland et al. showed that at least 60% of CRBSI could be traced to catheter hub contamination before the BSI. Just 20% of CRBSI were acquired through contamination of the cutaneous catheter tract. Cutaneous antisepsis before PICC placement prevents CRBSI by reducing catheter tract contamination and subsequent catheter tip colonization. A novel CHG-impregnated gauze at the catheter insertion site reduced CVC tip colonization risk when compared to PI cutaneous antisepsis, but did not reduce CRBSI rates in a randomized trial of over 700 neonates whose catheters were in situ an average of 17 ± 0.9 days. 26 The low CRBSI rate following catheter tract contamination in neonates will require a very large randomized trial to show that cutaneous CHG antisepsis is more efficacious than PI for the prevention CRBSI.
Cutaneous absorption of PI may compromise thyroid function in preterm infants, but does not appear to be a common cause of transient neonatal hypothyroidism in neonates in North America. 8, 9 Concern over iodine absorption in neonates is one reason given for exploring the use of CHG as an antiseptic in neonates. In this trial CHG was absorbed from the intact skin of neonates enrolled in the trial. Others have also shown cutaneous absorption of CHG in neonates. [27] [28] [29] The concentration of CHG found in the blood of enrolled neonates was similar to what others report. 29 Although the study was not designed to evaluate the pharmacokinetics of cutaneously absorbed CHG, at least two infant appeared to have increasing concentrations following each application suggesting accumulation through increased absorption or reduced metabolism and excretion of CHG. Although cutaneously applied CHG is absorbed through neonatal skin, there have been few reported side effects. Animal trials have shown no significant toxicity from CHG. 30 There were no significant systemic side effects in this trial or previous trials that evaluated CHG as a cutaneous antiseptic for neonates. 12, 24 This small pilot trial failed to detect contact dermatitis (95% UCL 5.7%) following cutaneous antisepsis with a 2% CHG before PICC insertion in neonates who were >1500 g and at least a week old. Neonates absorbed CHG. Before the widespread use of CHG for prevention of CRBSI in neonates, larger trials will be necessary to determine if CHG is more effective and as well-tolerated as PI.
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